• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

• 페이스북 공유
• 트위터 공유
• 

Personalized Depression Treatment

For many people gripped by depression, traditional therapies and medications are not effective. Personalized treatment may be the solution.

Cue is an intervention platform for digital devices that translates passively acquired normal sensor data from smartphones into customized micro-interventions to improve mental health. We analyzed the best-fitting personalized ML models to each subject using Shapley values, in order to understand their feature predictors. This revealed distinct features that changed mood in a predictable manner over time.

Predictors of Mood

depression treatments near me is a leading cause of mental illness around the world.1 Yet, only half of those with the condition receive treatment. To improve the outcomes, healthcare professionals must be able to identify and treat patients who have the highest likelihood of responding to particular treatments for depression.

The ability to tailor depression treatment ect treatments is one method of doing this. Using mobile phone sensors, an artificial intelligence voice assistant, and other digital tools researchers at the University of Illinois Chicago (UIC) are working on new ways to predict which patients will benefit from the treatments they receive. Two grants totaling more than $10 million will be used to discover biological and behavioral factors that predict response.

The majority of research to so far has focused on sociodemographic and clinical characteristics. These include factors that affect the demographics such as age, sex and educational level, clinical characteristics like symptom severity and comorbidities, and biological markers like neuroimaging and genetic variation.

While many of these factors can be predicted from data in medical records, very few studies have employed longitudinal data to study the factors that influence mood in people. Many studies do not take into consideration the fact that mood can differ significantly between individuals. Therefore, it is essential to develop methods that allow for the recognition of different mood predictors for each person and alternative treatments for depression effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can systematically identify distinct patterns of behavior and emotions that differ between individuals.

In addition to these methods, the team developed a machine-learning algorithm to model the changing factors that determine a person's depressed mood. The algorithm integrates the individual characteristics to create an individual "digital genotype" for each participant.

This digital phenotype was correlated with CAT-DI scores, which is a psychometrically validated scale lithium for treatment resistant depression assessing severity of symptom. However the correlation was not strong (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely across individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1 but is often not properly diagnosed and treated. In addition, a lack of effective treatments and stigmatization associated with depressive disorders prevent many from seeking treatment.

To help with personalized treatment, it is essential to identify predictors of symptoms. However, current prediction methods rely on clinical interview, which has poor reliability and only detects a small number of features that are associated with depression.2

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous digital behavioral patterns gathered from sensors on smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes are able to are able to capture a variety of distinct behaviors and activities, which are difficult to record through interviews and permit high-resolution, continuous measurements.

The study included University of California Los Angeles (UCLA) students who were suffering from moderate to severe depressive symptoms. enrolled in the Screening and Treatment for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment in accordance with their severity of depression. Patients with a CAT DI score of 35 65 students were assigned online support with an instructor and those with a score 75 were sent to in-person clinics for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their demographics and psychosocial characteristics. The questions asked included age, sex, and education as well as financial status, marital status as well as whether they divorced or not, their current suicidal thoughts, intent or attempts, as well as How Depression Is Treated (Https://Ai-Db.Science/Wiki/It_Is_The_History_Of_Depression_Treatment_Guidelines) often they drank. The CAT-DI was used to rate the severity of depression-related symptoms on a scale of 0-100. The CAT DI assessment was carried out every two weeks for those who received online support and weekly for those who received in-person support.

Predictors of Treatment Response

Personalized depression treatment is currently a major research area, and many studies aim at identifying predictors that will allow clinicians to identify the most effective medications for each person. Pharmacogenetics, in particular, uncovers genetic variations that affect the way that our bodies process drugs. This enables doctors to choose drugs that are likely to work best for each patient, reducing the time and effort required in trials and errors, while avoid any adverse effects that could otherwise hinder progress.

Another promising approach is building models for prediction using multiple data sources, combining data from clinical studies and neural imaging data. These models can then be used to identify the best combination of variables that is predictors of a specific outcome, like whether or not a particular medication is likely to improve symptoms and mood. These models can be used to determine the patient's response to a treatment, allowing doctors maximize the effectiveness.

A new era of research uses machine learning methods like supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables and improve the accuracy of predictive. These models have been proven to be effective in predicting outcomes of treatment for example, the response to antidepressants. These methods are becoming popular in psychiatry and it is likely that they will become the norm for future clinical practice.

Research into the underlying causes of depression continues, as do ML-based predictive models. Recent findings suggest that the disorder is connected with neurodegeneration in particular circuits. This suggests that individual depression treatment will be focused on therapies that target these circuits in order to restore normal functioning.

One method to achieve this is by using internet-based programs that offer a more personalized and customized experience for patients. One study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring the best quality of life for those suffering from MDD. A controlled, randomized study of a personalized treatment for depression showed that a significant number of patients saw improvement over time as well as fewer side consequences.

Predictors of Side Effects

In the treatment of depression, the biggest challenge is predicting and determining which antidepressant medications will have minimal or zero side negative effects. Many patients are prescribed a variety of drugs before they find a drug that is safe and effective. Pharmacogenetics provides an exciting new way to take an effective and precise method of selecting antidepressant therapies.

There are a variety of variables that can be used to determine the antidepressant that should be prescribed, including gene variations, patient phenotypes such as gender or ethnicity and the presence of comorbidities. To identify the most reliable and accurate predictors of a specific treatment, random controlled trials with larger sample sizes will be required. This is because it could be more difficult to determine interactions or moderators in trials that comprise only one episode per person rather than multiple episodes over time.

Additionally, predicting a patient's response will likely require information on comorbidities, symptom profiles and the patient's own perception of effectiveness and tolerability. At present, only a few easily identifiable sociodemographic and clinical variables appear to be reliable in predicting the severity of MDD, such as gender, age race/ethnicity, SES BMI, the presence of alexithymia, and the severity of depression symptoms.

Many challenges remain when it comes to the use of pharmacogenetics to treat depression. First, it is essential to have a clear understanding and definition of the genetic factors that cause depression, as well as an understanding of a reliable indicator of the response to treatment. Ethics like privacy, and the responsible use genetic information should also be considered. In the long run, pharmacogenetics may offer a chance to lessen the stigma that surrounds mental health treatment and to improve the outcomes of those suffering with depression. Like any other psychiatric treatment, it is important to carefully consider and implement the plan. For now, the best option is to provide patients with an array of effective medications for depression and encourage them to talk with their physicians about their concerns and experiences.